![](https://www.lifesciencehistory.com/wp-content/uploads/2024/05/novartis-6.png)
Novartis commited to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
On Mar. 20, 2020, Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts, and will evaluate needs for additional clinical trials.
Tags:
Source: Amneal Pharmaceuticals, Inc.
Credit: